Highlights
-
The use of immunobiologicals is an option for the management of patients with chronic rinosinusitis with nasal polyps (CRSwNP) refractory to conventional treatment.
-
The guideline lists the main drugs currently available in Brazil, their indications, and recommendations for use.
Abstract
Introduction
Severe uncontrolled chronic rhinosinusitis with nasal polyps has a negative impact on an individual’s quality of life. Therefore, new biologics have emerged for use in specific phenotypes of chronic rhinosinusitis, changing the paradigms of its treatment.
Objective
To review the current status of biologic treatment indications in chronic rhinosinusitis.
Methods
The Brazilian Academy of Rhinology brought together different specialists to suggest a course of action, considering its particularities and aspects related to the national reality.
Results
Of particular interest for decision making will be the identification of subgroups of patients refractory to pre-existing treatment options and the construction of a strategy that improves their quality of life, with the best cost-benefit ratio.
Conclusion
The use of biologics is a valid option for treatment in more severe cases. This strategy must be better understood and improved in the future, with more studies and greater clinical experience.
Keywords
Immunobiologicals; Monoclonal antibody; Chronic rhinosinusitis; Nasal polyps